Semi-synthetic Ocotillol Analogues As Selective ABCB1-mediated Drug Resistance Reversal Agents

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Aug 23

PMID 26296969

Citations 24

Authors

Yun-Kai Zhang

Hengyuan Zhang

Guan-Nan Zhang

Yi-Jun Wang

Rishil J Kathawala

Rui Si

Bhargav A Patel

Jinyi Xu

Zhe-Sheng Chen

Affiliations

Soon will be listed here.

Abstract

Overexpression of ATP-Binding Cassette transporters leads to multidrug resistance in cancer cells and results in the failure of chemotherapy. In this in-vitro study, we investigated whether or not (20S, 24R/S)-epoxy-12β, 25-dihydroxy-dommarane-3β-amine (ORA and OSA), a pair of semi-synthetic ocotillol analogue epimers, could inhibit the ABCB1 transporter. ORA (1 μM and 3 μM) significantly reversed the resistance to paclitaxel and vincristine in ABCB1-overexpressing SW620/Ad300 and HEK/ABCB1 cells, whereas OSA had no significant effects. In addition, ORA (3 μM) significantly increased the intracellular accumulation of [3H]-paclitaxel by suppressing the efflux function of ABCB1. Meanwhile, both ORA (3 μM) and OSA (3 μM) did not significantly alter the expression level or the subcellular location of ABCB1 protein. Moreover, the ABCB1 ATPase study suggested that ORA had a stronger stimulatory effect on the ATPase activity than OSA. ORA also exhibited a higher docking score as compared with OSA inside transmembrane domain of ABCB1. Overall, we concluded that ORA reverse ABCB1-mediated MDR by competitively inhibiting the ABCB1 drug efflux function.

Citing Articles

Synthesis, Anti-Inflammatory Activities, and Molecular Docking Study of Novel Pyxinol Derivatives as Inhibitors of NF-κB Activation.

Tan S, Zou Z, Luan X, Chen C, Li S, Zhang Z Molecules. 2024; 29(8).

PMID: 38675532 PMC: 11052049. DOI: 10.3390/molecules29081711.

Design, Synthesis, and Anti-Inflammatory Activities of 12-Dehydropyxinol Derivatives.

Wang Y, Mi X, Du Y, Li S, Yu L, Gao M Molecules. 2023; 28(3).

PMID: 36770974 PMC: 9921557. DOI: 10.3390/molecules28031307.

Preclinical studies of the triazolo[1,5-]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor.

Wang S, Teng Q, Wang S, Lei Z, Hu H, Lv H Acta Pharm Sin B. 2022; 12(8):3263-3280.

PMID: 35967279 PMC: 9366537. DOI: 10.1016/j.apsb.2022.03.023.

Recent Advances in the Semisynthesis, Modifications and Biological Activities of Ocotillol-Type Triterpenoids.

Cao Y, Wang K, Xu S, Kong L, Bi Y, Li X Molecules. 2020; 25(23).

PMID: 33260848 PMC: 7730845. DOI: 10.3390/molecules25235562.

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells.

Zhang Y, Wu Z, Yang Y, Wang J, Li J, Sun Z Cancers (Basel). 2020; 12(11).

PMID: 33158067 PMC: 7694178. DOI: 10.3390/cancers12113249.

References

Li L, Chen X, Li D, Zhong D . Identification of 20(S)-protopanaxadiol metabolites in human liver microsomes and human hepatocytes. Drug Metab Dispos. 2010; 39(3):472-83. DOI: 10.1124/dmd.110.036723. View

Zhou Z, Ma C, Zhang H, Bi Y, Chen X, Tian H . Synthesis and biological evaluation of novel ocotillol-type triterpenoid derivatives as antibacterial agents. Eur J Med Chem. 2013; 68:444-53. DOI: 10.1016/j.ejmech.2013.07.041. View

Friesner R, Murphy R, Repasky M, Frye L, Greenwood J, Halgren T . Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006; 49(21):6177-96. DOI: 10.1021/jm051256o. View

Bansal T, Jaggi M, Khar R, Talegaonkar S . Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci. 2009; 12(1):46-78. DOI: 10.18433/j3rc77. View

Patel A, Tiwari A, Chufan E, Sodani K, Anreddy N, Singh S . PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemother Pharmacol. 2013; 72(1):189-99. PMC: 8366681. DOI: 10.1007/s00280-013-2184-z. View

Crivori P, Reinach B, Pezzetta D, Poggesi I . Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol Pharm. 2006; 3(1):33-44. DOI: 10.1021/mp050071a. View

Guo H, Zhang G, Wang Y, Zhang Y, Sodani K, Talele T . β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. Oncol Rep. 2013; 31(2):858-66. DOI: 10.3892/or.2013.2870. View

Dean M, Hamon Y, Chimini G . The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001; 42(7):1007-17. View

Klopman G, Shi L, Ramu A . Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol Pharmacol. 1997; 52(2):323-34. DOI: 10.1124/mol.52.2.323. View

10.

Liu J, Wang X, Liu P, Deng R, Lei M, Chen W . 20(S)-Protopanaxadiol (PPD) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs. Bioorg Med Chem. 2013; 21(14):4279-87. DOI: 10.1016/j.bmc.2013.04.067. View

11.

Coley H . Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol. 2009; 596:341-58. DOI: 10.1007/978-1-60761-416-6_15. View

12.

Zhang Y, Wang Y, Gupta P, Chen Z . Multidrug Resistance Proteins (MRPs) and Cancer Therapy. AAPS J. 2015; 17(4):802-12. PMC: 4476997. DOI: 10.1208/s12248-015-9757-1. View

13.

Thomas H, Coley H . Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003; 10(2):159-65. DOI: 10.1177/107327480301000207. View

14.

Kathawala R, Gupta P, Ashby Jr C, Chen Z . The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015; 18:1-17. DOI: 10.1016/j.drup.2014.11.002. View

15.

Li J, Jaimes K, Aller S . Refined structures of mouse P-glycoprotein. Protein Sci. 2013; 23(1):34-46. PMC: 3892297. DOI: 10.1002/pro.2387. View

16.

Twentyman P, Fox N, White D . Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer. 1987; 56(1):55-7. PMC: 2001675. DOI: 10.1038/bjc.1987.153. View

17.

Modok S, Mellor H, Callaghan R . Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 2006; 6(4):350-4. DOI: 10.1016/j.coph.2006.01.009. View

18.

Krishna R, Mayer L . Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000; 11(4):265-83. DOI: 10.1016/s0928-0987(00)00114-7. View

19.

Tiwari A, Sodani K, Dai C, Ashby Jr C, Chen Z . Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 2010; 12(4):570-94. DOI: 10.2174/138920111795164048. View

20.

Baer M, George S, Dodge R, OLoughlin K, Minderman H, Caligiuri M . Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002; 100(4):1224-32. View